Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

113 - Effective treatment of nasopharyngeal carcinoma with autologous Epstein-Barr Virus and oncogene–targeted cytotoxic t lymphocytes

Date

14 Dec 2018

Session

Poster Display session

Presenters

Weixiong Xia

Citation

Annals of Oncology (2018) 29 (suppl_10): x11-x16. 10.1093/annonc/mdy485

Authors

W. Xia, L. Guoying, Y. Xiang

Author affiliations

  • Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
More

Resources

Abstract 113

Background

The outcomes for patients with metastatic or locally recurrent Epstein–Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) remain poor. We aimed to improve the outcomes for NPC refractory to conventional treatments with autologous EBV and oncogene–targeted Cytotoxic T Lymphocytes (CTL) therapy.

Methods

Patients with stage IV NPC who cannot tolerate chemotherapy received autologous EBV and oncogene–targeted CTL expanded ex vivo from peripheral blood lymphocytes through dendritic cells (DCs) transfected by adenovirus-based vector encoded multiple epitopes from LMP1, CK19, survivin, SCC, CEA, SPANX, MAGE-A3, PMSA. Clinical tumor responses, survival rate and toxicity were evaluated.

Results

In total 16 patients received multiple oncogenes-targeted CTL infusion. Among them, 2 patients had locally advanced NPC (LANPC) with high-risk distance metastasis, 5 patients had nasopharyngeal and/or cervical recurrence after re-irriadiation or surgery, 7 patients had distant metastasis and 2 patients had both distant metastasis and nasopharyngeal recurrence. Three patients showed CR, one patient showed PR, and nine patients exhibited SD after CTL infusion. During a median follow-up of 15 months, the median progression-free survival (PFS) was 282 days (range 28-503 days), the mean overall survival is 484 days (range 28–552 days) after autologous CTL infusion. We did not observe severe or chronic adverse reactions related to autologous EBV and oncogene–targeted CTL infusions.

Conclusions

In our study, our findings show that therapy with autologous Epstein-Barr Virus and oncogene–Targeted Cytotoxic T Lymphocytes is safe and well tolerated and may offer clinical benefit to patients with NPC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sun Yat-Sen University Cancer Center.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.